Advancements in anemias related to chronic conditions (Q37771336)

22 August 2017

1 reference

title

Advancements in anemias related to chronic conditions (English)

1 reference

22 August 2017

Gian Cesare Guidi

1

1 reference

22 August 2017

Clara Lechi Santonastaso

series ordinal

2

1 reference

22 August 2017

publication date

1 September 2010

1 reference

Clinical Chemistry and Laboratory Medicine

22 August 2017

published in

1 reference

22 August 2017

volume

48

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

1217-1226

1 reference

Recommendations for reference method for haemoglobinometry in human blood (ICSH standard 1995) and specifications for international haemiglobinocyanide standard (4th edition).

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Clinical utility of the new Beckman-Coulter parameter red blood cell size factor in the study of erithropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Quality counts: new parameters in blood cell counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Pathogenesis and treatment of anaemia of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

The potential impact of anaemia of chronic disease in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

An update on iron physiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Anemia in renal disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

The kit ligand: A cell surface molecule altered in steel mutant fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

The ins and outs of iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Tumour necrosis factor alpha causes hypoferraemia and reduced intestinal iron absorption in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Iron Deficiency and Erythropoiesis: New Diagnostic Approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

The molecular mechanism of hepcidin-mediated ferroportin down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Balancing acts: molecular control of mammalian iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Duodenal expression of iron transport molecules in untreated haemochromatosis subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Mechanisms of iron loading and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Iron absorption and metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Iron imports. IV. Hepcidin and regulation of body iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Cellular iron: ferroportin is the only way out

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Suppression of hepcidin during anemia requires erythropoietic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hereditary iron overload: update on pathophysiology, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hepcidin: from discovery to differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hepcidin modulation in human diseases: from research to clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

The burden of kidney disease: improving global outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hemoglobin level variability: anemia management among variability groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Pathogenesis of renal anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Purification and characterization of hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hypoxia and the HIF system in kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Is hepcidin the star player in iron metabolism in chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Transdifferentiation of cultured tubular cells induced by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Soluble Transferrin Receptor (sTfR): Biological Variations and Reference Limits

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.264

21 January 2018

Identifiers

DOI

10.1515/CCLM.2010.264

1 reference

22 August 2017

1 reference